Heidelberg Pharma AG
XETRA:HPHA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.17
3.85
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one HPHA stock under the Base Case scenario is 2.65 EUR. Compared to the current market price of 2.28 EUR, Heidelberg Pharma AG is Undervalued by 14%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Heidelberg Pharma AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for HPHA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Heidelberg Pharma AG
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Heidelberg Pharma AG
Balance Sheet Decomposition
Heidelberg Pharma AG
Current Assets | 52.4m |
Cash & Short-Term Investments | 36.6m |
Receivables | 3.2m |
Other Current Assets | 12.7m |
Non-Current Assets | 13.4m |
PP&E | 3.5m |
Intangibles | 8.9m |
Other Non-Current Assets | 975.3k |
Current Liabilities | 8.7m |
Accounts Payable | 5.2m |
Other Current Liabilities | 3.5m |
Non-Current Liabilities | 21.2m |
Long-Term Debt | 21.2m |
Earnings Waterfall
Heidelberg Pharma AG
Revenue
|
8.5m
EUR
|
Cost of Revenue
|
-1.7m
EUR
|
Gross Profit
|
6.8m
EUR
|
Operating Expenses
|
-27.2m
EUR
|
Operating Income
|
-20.4m
EUR
|
Other Expenses
|
1.6m
EUR
|
Net Income
|
-18.8m
EUR
|
Free Cash Flow Analysis
Heidelberg Pharma AG
EUR | |
Free Cash Flow | EUR |
HPHA Profitability Score
Profitability Due Diligence
Heidelberg Pharma AG's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
Heidelberg Pharma AG's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
HPHA Solvency Score
Solvency Due Diligence
Heidelberg Pharma AG's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Heidelberg Pharma AG's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HPHA Price Targets Summary
Heidelberg Pharma AG
According to Wall Street analysts, the average 1-year price target for HPHA is 11.53 EUR with a low forecast of 11.41 EUR and a high forecast of 11.87 EUR.
Dividends
Current shareholder yield for HPHA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
HPHA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
Contact
IPO
Employees
Officers
The intrinsic value of one HPHA stock under the Base Case scenario is 2.65 EUR.
Compared to the current market price of 2.28 EUR, Heidelberg Pharma AG is Undervalued by 14%.